Skip to main content
US EQUITIES CLOSED CRYPTO 24/7
HALAL TRADING ROOM Sharia-screened signals
TERMINAL
RG

RGENStockRepligen Corp.

Nasdaq Global Select Market · Healthcare · US

$176.94 last close 2026-10-30
Open in terminalCompare
Alert

Verdicts genuinely change. Free email alert the moment RGEN's does — no target price to set, unlike "Alert" above.

Sharia status
NOT YET SCREENED
Not screened yet — no methodology has been established for this symbol
🕌 Held by MNZL HTR non-permissible income 19.52%

Methodology breakdown computing — it will appear here on its own.

🕌Open research, not a fatwa — verify with your own scholar.

Trade setup

Whether the technical picture shows an edge right now. Separate from the Sharia verdict, which this side never overrides.

SEPARATE FROM SHARIAH
No active setup right now. The technical picture doesn't show a clear edge — check back when the trend or momentum shifts.

Trade plan

Posted with a stop, a target and the level that invalidates it. It resolves into the public record either way.

MOM · SCALP
Entry
$173.50
Stop
$171.76
Target
$176.97
Risk : Reward 2.0R

Why this signal?

The factors behind the read, each shown with the figure it rests on, including the ones pointing the other way.

Structure3 of 5 timeframes bullish · 56.5% aligned
VWAPPrice below VWAP ($177.87)
VolumeRelative volume 6.9× the 20-day average
Momentum10-day rate of change +2.6%
Market & analysts
Price target
$203.42
+15.0% · 19 analysts
Institutional own.
106.5% *
of shares
Momentum (10d)
+2.6%
rate of change
SMC grade
D · 36
56.5% aligned
🕌 MNZL
Held by real halal ETF(s)
3.60% *
Purification ratio (secondary provider, uncertain)
19.52%
Non-permissible income — HTR, from filings (2025-12-31)
D · 36
SMC grade — 56.5% timeframe alignment
+2.6%
Rate of change (10d)
$203.42
Price target (+15.0%) · 19 analysts
106.5%
Institutional ownership *

🕌 In-house Compliance Research

Computing the full ratio and business-activity breakdown for RGEN — this runs off the critical path so the page paints first. It will appear here on its own.

Tracked investors holding RGEN
InvestorFirmPositionWeightAs of
Stanley Druckenmiller Duquesne Family Office $11M 0.2% 2026-06-30
Azzad Asset Management Azzad Asset Management $0M 0.0% 2026-06-30

From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.

194.57171.65148.72125.80102.872025-11-032026-05-052026-10-30

Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset

Support & Resistance
S3
179.83
S2
182.55
S1
185.60
PIVOT
188.32
R1
191.37
R2
194.09
R3
197.14

Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.

Price Forecast

The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally below. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.

7-day expected range
171.57 – 204.11
±8.66% from 187.84, made 2026-09-25 · resolves 2026-10-02
STRONG BUY
from 19 indicators
61.9% of our last 5789 forecasts — across every instrument we forecast, not just this one — landed inside their stated range, and 49.9% called the direction correctly.

Technical Summary

Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.

BUY
19 indicators
OscillatorsSTRONG BUY
3 buy · 4 neutral · 0 sell
Moving averagesSELL
5 buy · 0 neutral · 7 sell
Every indicator, and what it reads
IndicatorValueSignal
RSI (14)48.70NEUTRAL
Stochastic %K (14)46.08NEUTRAL
CCI (20)-15.35NEUTRAL
Williams %R (14)-53.92NEUTRAL
MACD (12,26,9)0.27BUY
ROC (10)0.87BUY
Momentum (10)1.52BUY
EMA (10)180.12SELL
SMA (10)179.72SELL
EMA (20)179.28SELL
SMA (20)177.61SELL
EMA (30)178.26SELL
SMA (30)180.81SELL
EMA (50)174.65BUY
SMA (50)178.05SELL
EMA (100)165.07BUY
SMA (100)162.00BUY
EMA (200)155.47BUY
SMA (200)144.76BUY

About Repligen Corp.

Healthcare · Medical Instruments & Supplies

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

repligen.com ↗

Background via Yahoo Finance — informational, not part of the verdict.

Latest Signal — 2026-10-09

MOM
Type · SCALP
173.50
Entry
171.76
Stop
176.97
Target
LOSS
Outcome

Stop 171.76 Now 176.94 Target 176.97

Grade verdict

Weak — low conviction, small size or skip

SMC — Top Down

Market structure by timeframe, read from real bars. A bias per timeframe rather than a forecast — timeframes disagreeing is information, not noise.

TimeframeBiasBars
📅 Daily BULLISH 64
⏰ 4H RANGING 35
🕐 1H RANGING 98
⏱ 15-Min BULLISH 130
⏲ 5-Min BULLISH 234

Momentum & Volume

Rate of change and relative volume against this symbol's own recent history. Momentum describes what price has done; it is not a claim about what it will do.

+2.6%
Rate of change (10d)
6.9×
Volume vs its 20-day average
1.29
MACD (no fresh cross)

Peer Movement

How the rest of the sector moved over the same window. Context for a price move, never a cause of one.

Peer movement computing — it will appear here on its own.

Before you act on this

The questions worth asking about any verdict on this page, answered plainly.

Is this a fatwa?

No. HTR applies published screening standards to a company's own filings and shows the result under each one. It is research, not a religious ruling. For a ruling that applies to you, ask a qualified scholar.

Why can the standards disagree?

Because they measure different things. Some divide interest-bearing debt by market cap, others by total assets, and the thresholds differ too. The same filing can clear one line and cross another. HTR shows every verdict rather than averaging them into one label.

How often is this re-screened?

Ratios are recomputed when a new filing lands, and the whole watchlist is re-screened on a rolling basis. The date on the verdict above is the last time this symbol was actually recomputed, not the last time the page was built.

Do I need to purify dividends?

If a company earns some non-permissible income, many scholars hold that the same share of any dividend should be given away. The non-permissible income figure above is the number that calculation starts from — the purification calculator finishes it, showing the filing figures behind the ratio and both the proportional and the AAOIFI per-share convention.

Open research, not a fatwa. HTR applies published screening standards to filings and publishes what they say, including when they disagree. Nothing here is financial advice or a recommendation to buy or sell. Verdicts can change when new filings land.

Compare with

Same screen, different answers. Comparison is where the standards disagreeing becomes useful rather than confusing.

Peer screening computing — it will appear here on its own.

Insider Activity (90d)

Insider transactions reported in the last ninety days. Insiders sell for reasons that have nothing to do with a view, so a sale on its own is not a signal.

NO DATA   0 buys · 0 sells

COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE

The weekly CFTC Commitments of Traders report for the broad market it tracks, not for this symbol. Positioning context for the tape — it says nothing about this company.

NEUTRAL   report date 2026-10-27 · Asset managers net 923449 (+22072)

AI Summary

Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.

Tell us what's working, what's confusing, or what you want to see next — read by a real person, not a form that goes nowhere.